How Should We Measure and Deal with Office Blood Pressure in 2021?

Vischer, Annina S.; Burkard, Thilo

doi:10.3390/diagnostics11020235

Cited by 8 publications

(9 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three office blood pressure measurements were obtained by properly calibrated mercury sphygmomanometer at each visit by the same operator. A standard operating procedure for measuring BP was followed [ 9 – 11 ]. For each patient, BP was measured twice at 30-s intervals.…”

Section: Methodsmentioning

confidence: 99%

Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy

Sultan

Rabea

Elberry³

et al. 2022

Egypt Heart J

View full text Add to dashboard Cite

Background Pulse wave velocity (PWV) and central blood pressure (CBP) have been intoduced into managment of hypertensive patients. PWV is positively correlated with arterial wall stiffness while central aortic pressure becomes better predictor of cardiovascular outcome than peripheral pressure. Reduction in CBP provides protective properties against subclinical organ damage. This work aims to investigate the effect of a new combination therapy of Amlodipine/Nebivolol (A/N) on central BP, peripheral BP and PWV. The results of using this combination will be compared to the well-established fixed-dose combination of Amlodipine/Valsartan (A/V). The study conducted between October 2018 and August 2020. One hundred and two hypertensive patients were assigned for Amlodipine 10 mg/Valsartan 160 mg combination therapy (A/V, n = 52) or Amlodipine 10 mg/Nebivolol 5 mg combination therapy (A/N, n = 50) by simple 1:1 randomization. Office, central blood pressure and PWV were measured on first (0 week), second (4–8 weeks) and third visit (10–12). Difference in BP (in each arm and between arms) was calculated along all visits. Results No statistical significant difference was found between A/V and A/N regarding age, gender, BMI and CV history. OBP, CBP and PWV were significantly reduced in each arm, but no differences were found when comparing both arm results to each other. Recorded side effects were insignificant. Conclusions The new combination therapy Amlodipine/Nebivolol (A/N) affords a significant reduction in CBP, PBP and PWV with minor and tolerable side effects. It has provided comparable results to Amlodipine/Valsartan (A/V) combination therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy

Sultan

Rabea

Elberry³

et al. 2022

Egypt Heart J

View full text Add to dashboard Cite

show abstract

“…AH: This included diagnosed patients undergoing treatment for AH at admission. It also included patients in whom an arterial systolic pressure of 140/90 mmHg was recorded, at least three times, after a minimum period of seven days following alcohol withdrawal, as recommended by most guidelines [21].…”

Section: Diagnosis Of Factors Studiedmentioning

confidence: 99%

Do Overweight, Arterial Hypertension and Type 2 Diabetes Worsen Cognitive Impairment in Patients with Alcohol Use Disorders?

Perney¹,

Nalpas²,

Alarcon³

et al. 2022

austinjpsychiatrybehavsci

View full text Add to dashboard Cite

Objective: Overweight, Arterial Hypertension (AH) and diabetes are frequently associated with alcohol use disorders. As each of these co-morbidities is independently associated with cognitive impairment, we studied whetherthey could worsen alcohol-related cognitive impairment. Methods: A retrospective analysis of a clinical database of patients with an alcohol use disorder admitted to an addiction treatment unit of a teaching hospital. Patient weight was classified using WHO recommendations; arterial hypertension and Type 2 diabetes were diagnosed according to the most recent guidelines. Cognitive status was assessed using the MoCA administered on admission and at discharge by trained staff members. Results: Among the 387 patients included (69.3% male, mean age 50.4), 6.4% suffered from Type II diabetes, AH was present in 22.4% of the sample, and 20.6% were obese (BMI>=30). MoCA scores at admission did not differ as a function of BMI, or AH or Type II diabetes status. At discharge, MoCA scoreshad improved in all subgroups; however, a multivariate analysis showed that they had improved significantly less in the AH group compared to the non-AH group. Conclusions: Our results confirm the impact of hypertension on cognitive dysfunction, including in patients with severe alcohol use disorders. Monitoring of blood pressure levels is, therefore, an important preventive measure for cognitive dysfunction in these patients.

show abstract

“…Arterial hypertension (AHT) is the leading preventable cause of premature death worldwide, with almost a third of the world population affected 1 . To diagnose AHT it is crucial to measure the blood pressure (BP) accurately 2 . According to the guidelines, these measurements should be taken using a device which has been validated according to standardized conditions and protocols 3 .…”

Section: Introductionmentioning

confidence: 99%

“… 1 To diagnose AHT it is crucial to measure the blood pressure (BP) accurately. 2 According to the guidelines, these measurements should be taken using a device which has been validated according to standardized conditions and protocols. 3 Additionally, we are increasingly confronted with the occurrence of smart phone technology and wearable devices which claim to be able to measure BP, and therefore need to be properly assessed to prove reliability.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A model for early failure prediction of blood pressure measurement devices in a stepped validation approach

Vischer

Dutilh

Socrates

et al. 2022

J of Clinical Hypertension

Self Cite

View full text Add to dashboard Cite

Blood pressure monitoring (BPM) devices have to be validated according to strict international validation protocols. Each protocol requests a specific number of participants to be included. All protocols use vast amounts of resources, as three people have to be present for every measurement, making trials costly, especially when the manufacturer has no intention to execute a validation study, reflected in the low share of validated in the commercially available BPM devices. The aim of our study was to develop criteria, which could detect low accuracy devices that could not pass a validation protocol early in the course of the validation process. The 2010 European Society of Hypertension International Protocol (ESH-IP) and the Universal Standard for Validation of BPM devices (AAMI/ESH/ISO) were scrutinized for criteria which can be used for preclusion of passing. Based on this, we developed a fail model. We found that a BPM device cannot pass the ESH-IP protocol, if there are ≥27, 13, or 4 single measurements differing more than 5, 10, or 15 mmHg, respectively, from the reference. For the AAMI/ESH/ISO protocol, we developed a model, which calculates best-case standard deviations (SDs) to detect SDs which would prevent the passing of the protocol before its completion, making a stepwise validation process possible. In conclusion, we found that our model is able to predict failure of low-accuracy BPM devices early during a validation protocol if used in a stepwise-approach. This can be useful to keep costs of validation studies low and to enable investigator-initiated trials. K E Y W O R D Sblood pressure measurement, fail criteria, home blood pressure measurement, validation protocol INTRODUCTIONArterial hypertension (AHT) is the leading preventable cause of premature death worldwide, with almost a third of the world populationThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

How Should We Measure and Deal with Office Blood Pressure in 2021?

Cited by 8 publications

References 70 publications

Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy

Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy

Do Overweight, Arterial Hypertension and Type 2 Diabetes Worsen Cognitive Impairment in Patients with Alcohol Use Disorders?

A model for early failure prediction of blood pressure measurement devices in a stepped validation approach

Contact Info

Product

Resources

About